Compare Incyte Corporation (INCY) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SOLAI Limited — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Incyte Corporation is far larger — about 1384.7× SOLAI Limited's market cap, and Incyte Corporation is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| INCY | SLAI | |
|---|---|---|
Market Cap | $23.11B | $16.69M |
Sector | Health | Technology |
52-Week High | $118.52 | $26.74 |
52-Week Low | $67.38 | $2.74 |
Enterprise Value | $19.13B | $16.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLAI trades at $3.72 with no recent price movement, while facing NYSE delisting proceedings announced July 16, 2026. The company shows severe financial distress with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Recent developments include a 7:1 reverse stock split effective June 2026 and acquisition of a 51% stake in NEURALAND. Technical indicators show mixed signals with an overall bullish trend but overbought RSI conditions.
The outlook remains highly speculative given delisting risks and persistent losses. Investment opportunity exists only for speculative traders betting on turnaround potential from recent acquisitions and AI product launches. Primary risks include imminent delisting, negative cash flow, and unsustainable financial performance that threatens ongoing operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
